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Abstract Heritable changes in gene expression that are not
based upon alterations in the DNA sequence are defined as
epigenetics. The most common mechanisms of epigenetic
regulation are the methylation of CpG islands within the
DNA and the modification of amino acids in the N-terminal
histone tails. In the last years, it became evident that the
onset of cancer and its progression may not occur only due
to genetic mutations but also because of changes in the
patterns of epigenetic modifications. In contrast to genetic
mutations, which are almost impossible to reverse, epige-
netic changes are potentially reversible. This implies that
they are amenable to pharmacological interventions. There-
fore, a lot of work in recent years has focussed on the
development of small molecule enzyme inhibitors like
DNA-methyltransferase inhibitors or inhibitors of histone-
modifying enzymes. These may reverse misregulated
epigenetic states and be implemented in the treatment of
cancer or other diseases, e.g., neurological disorders. Today,
several epigenetic drugs are already approved by the FDA
and the EMEA for cancer treatment and around ten histone
deacetylase (HDAC) inhibitors are in clinical development.
This review will give an update on recent clinical trials of
the HDAC inhibitors used systemically that were reported
in 2009 and 2010 and will present an overview of different
biomarkers to monitor the biological effects.
Epigenetics
Heritable changes in gene expression that are not based
upon alterations in the DNA sequence are defined as
epigenetics. The most common mechanisms of epigenetic
regulation are the methylation of CpG islands within the
DNA and the modification of amino acids in the N-terminal
histone tails, especially reversible histone acetylation (Jones
and Baylin 2007). While these modifications constitute the
biochemical basis for epigenetics, not necessarily always,
epigenetics is addressed when they are investigated. Thus,
the term epigenetics is used in many studies, although, e.g.,
only transient changes of histone modifications or in gene
regulation are monitored. This is also true for epigenetic
therapy because in the strictest sense it has to be shown
whether the daughter cell generation is cured. Especially in
the clinical setting, it might be difficult to show whether
immature cancer cells are induced to differentiate based
upon epigenetic phenomena or whether they have been
killed by cytotoxic effects.
It became increasingly evident that cancer formation and
persistence may not only be caused by genetic mutations
but also because of changes in the patterns of epigenetic
modifications. In contrast to genetic mutations, which are
basically irreversible, epigenetic changes are potentially
reversible (Yoo and Jones 2006). This implies that they are
amenable to pharmacological interventions (Santos-Rosa
and Caldas 2005).
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Modifications of the N-terminal tails of histone proteins
play a crucial role in chromatin packaging and gene
expression. Among these numerous modifications, reversible
acetylation of lysine residues has been studied most exten-
sively. Histone acetyltransferases transfer acetyl moieties to
lysines in the N-terminal histone tails by use of the cofactor
acetyl-CoA. This results in the neutralization of the negative
charge of the nitrogen in the ε-amino-group of the lysine
residue which in turn leads to a more open form of chromatin
(euchromatin) that is associated with activation of gene
expression. The acetyl groups are in turn cleaved off by
histone deacetylases leading to a more condensed form of
chromatin (heterochromatin) and gene silencing. In the last
years, it became evident, that histone acetylation and histone
deacetylases (HDACs) are not only linked with gene
repression but also with transcriptional activation. Wang et
al. (2009) could show that HDACs are also located at active
gene loci. They suggest that the acetylation-induced gene
expression needs to be reset before a new activation can be
initiated and that HDACs play a role in the reset of active
genes (2009).
The family of HDACs comprises of four classes, based
on their homology to yeast proteins. Three (class I, II, IV)
of these are zinc-dependent amidohydrolases, whereas class
III requires NAD
+ for the deacetylation reaction. Until
today, a total of 18 family members are known in humans,
class I consists of HDAC 1, 2, 3, and 8 and is homologous
to the yeast enzyme rpd3. This class is predominantly
located in the nucleus. Class II shows homology to the
yeast protein hda1 and comprises of six members (Verdin et
al. 2004). They can be subdivided into class IIa with the
subtypes HDAC 4, 5, 7, and 9 and the class IIb which
covers HDAC 6 and 10. Class IIb enzymes have two
catalytic sites, although one HDAC domain of HDAC10 is
lacking the active pocket residues required for the enzy-
matic activity (Verdin et al. 2003). First studies suggested
that the two HDAC domains of HDAC6 might function
independently, but more recent data shows that both
domains are required for the catalytic activity (Zhang et
al. 2006). The class II subtypes shuttle between the
cytoplasm and the nucleus (Yoo and Jones 2006). The only
member of class IV known today is HDAC 11. The
members of the class III HDACs are homologous to the
yeast-silencing protein Sir2 (Sauve et al. 2006). Several
members are located exclusively to the mitochondria.
Besides histones, many other proteins are substrates for
reversible protein acetylation. Among the best studied are
α-tubulin (target of HDAC6) and p53. From the target
point of view, it might no longer be correct to call these
enzymes histone deacetylases. Some researchers prefer
protein deacetylases but most reports stick to the historical
term (Buchwald et al. 2009; Glozak et al. 2005). This is due
to tradition but also because the major phenotypic
responses are thought to be mediated by histone deacety-
lation. Still, the relative roles of histone vs. non-histone
effects on phenotypic response have to be dissected in
further detail. While for transcriptional effects clearly
histone acetylation is involved, apoptotic processes will
likely also be influenced by inhibition of deacetylation of
other protein substrates, e.g., p53, hsp90 or tubulin. In the
clinical settings, more detailed analyses of unselective
versus class I selective inhibitors should shed light on this
in the future, Additionally, HDAC6 selective inhibitors
allow to address some of these questions (Scott et al. 2008).
HDACs and cancer
In recent years, it became evident that HDACs are
promising therapeutic targets with the potential to reverse
aberrant epigenetic states associated with cancer (Bolden et
al. 2006). Various studies in cancer cell lines and tumor
tissue revealed changes in the acetylation levels and the
expression of the HDAC enzymes (Bolden et al. 2006). In
hematologic malignancies, the aberrant recruitment of
HDACs to promoters plays a causal role in tumorigenesis
(Pandolfi 2001). Chromosomal translocations, which are
common in these diseases or overexpression of repressive
transcription factors create oncogenic DNA-binding fusion
proteins that physically interact with HDACs. Acute
promyelocytic leukemia was the first model disease in
which the involvement of HDACs in cancer onset was
demonstrated on a molecular level (Minucci and Pelicci
2006). Here, 100% of the patients show formation of fusion
proteins of the retinoic acid receptor-α with the promyelo-
cytic leukemia, the promyelocytic zinc finger, or other
proteins. These fusion proteins recruit HDAC-containing
repressor complexes that constitutively repress the expres-
sion of specific target proteins (Pandolfi 2001). B-cell
lymphoma 6 is an example for a transcriptional repressor
which recruits complexes containing HDAC enzymes.
These complexes cause activation of BCL-6 resulting in
transcriptional silencing. BCL-6 is overexpressed in 40% of
diffuse large B-cell lymphomas (Pasqualucci et al. 2003).
Moreover, the expression of the HDAC enzymes
themselves can be up- or downregulated in various types
of cancer. However, most studies show that there is a
considerable variation in the expression levels between
tumors of the same entity. In general, expression of class I
HDACs tended to be higher in tumor samples compared to
the corresponding normal tissue. In contrast, class II
HDACs seemed to be downregulated and high expression
correlated with a better prognosis (Weichert 2009).
Increased HDAC activity leads to hypoacetylation of target
118 Clin Epigenet (2010) 1:117–136proteins, e.g., histones in the promoter area of tumor
suppressor genes, thus resulting in transcriptional repression
(Santos-Rosa and Caldas 2005). Interestingly, mutations in
genes encoding for HDACs are rarely found in cancer
(Lafon-Hughes et al. 2008). So far, only one truncating
mutation of HDAC2 in colorectal and endometrial tumors
has been described. Somatic HDAC4 mutations were found
in breast and colorectal cancer and there are reports about
germline polymorphisms in different HDACs. The functional
significance for these sequence alterations is not clear yet
(Ganesan et al. 2009).
Effects of HDAC inhibition
HDAC inhibitors cause changes in the acetylation status of
chromatin and other non-histone proteins, resulting in
changes in gene expression, induction of apoptosis, cell
cycle arrest, and inhibition of angiogenesis and metastasis
(Ma et al. 2009). In general, these small molecule inhibitors
show a higher sensitivity towards transformed cells as
compared to normal cells (Qui et al. 1999; Parsons et al.
1997). The overall number of genes regulated by HDACs is
relatively small (Van Lint et al. 1996). The genes induced
by HDAC inhibitors are mainly involved in cell growth,
differentiation, and survival.
HDACi were first discovered as a result of their ability
to induce cellular differentiation (Leder et al. 1975). This
effect is associated with their ability to cause cell cycle
arrest in G1 and/or G2 phase, thus leading to inhibition of
cell growth (Bolden et al. 2006). The concentrations
necessary to cause growth inhibition correlate very well
with those needed to induce hyperacetylation of histones
(Richon et al. 1998). G1 cell cycle arrest is, in most cases, a
result of the induction of the CDKN1A gene, which
encodes the cyclin-dependent kinase inhibitor WAF1 (also
known as p21; Richon et al. 2000). Treatment of cells with
HDACi can also lead to the induction of apoptosis. The
inhibitors can initiate extrinsic (death receptor) and intrinsic
(mitochondrial) pathways (Ma et al. 2009). It has been
shown that various members of the TNF receptor super
family and ligands become transcriptionally activated upon
HDACi treatment (Bolden et al. 2006). The HDACi-
induced activation of the intrinsic apopotic pathway is not
fully understood today. One possibility is that HDACi
cause global changes in gene expression that alter the
balance of expression of pro- and antiapoptotic proteins. It
is also possible that HDACi can activate a defined protein
or signaling pathway; thus, inducing the intrinsic apoptotic
pathway (Bolden et al. 2006).
Burgess et al. (2004) could show that histone deacetylase
inhibitors also kill nonproliferating tumor cells, whereas
normal cells remain unaffected. This is an advantage over
most classical anti-cancer agents that only target the
proliferating cell population of a tumor and thus bearing
t h er i s ko far e l a p s e .I nam o u s em o d e lo fc h r o n i c
myelogenous leukemia (CML), the HDACi Panobinostat
in combination with Imatinib mesylate was able to deplete
CML leukemia stem cells and thus preventing a relapse
after therapy discontinuation (Zhang et al. 2010). A clinical
trial of the above mentioned combination in CML patients
is underway.
Furthermore, HDACi have been described to have
antiangiogenic and antimetastatic effects. Their antiangio-
genic properties result from a decrease in expression of
proangiogenic genes like vascular endothelial growth factor
and endothelial nitric oxide synthase (Deroanne et al. 2002;
Michaelis et al. 2004; Rössig et al. 2002). These effects also
contribute to a decreased nutrient supply of the metastasis,
thus leading to an inhibition of the metastatic spread of the
tumor (Bolden et al. 2006). Upregulation of gene expres-
sion of metastatic suppressors and downregulation of genes
that promote metastasis were also described to be responsible
for the antimetastatic effects of HDACi (Mudduluru et al.
2004;M a z i è r e se ta l .2007; Liu et al. 2003).
Growing evidence shows that HDACi have immuno-
modulatory effects. This can result in an increased
recognization of malignant cells by the immune system
due to an increased presence of surface antigens. For
example, it has been shown that HDACi can upregulate the
expression of major histocompatibility complex class I and
II proteins (Magner et al. 2000). Additionally, HDACi can
enhance immune cell activity by altering cytokine secre-
tion. But the HDAC inhibitor suberoylanilide hydroxamic
acid (SAHA, INN: Vorinostat) has also been demonstrated
to suppress the production of pro-inflammatory cytokines
that play a role in the pathogenesis of acute graft-versus-
host disease (GVHD) (Reddy et al. 2004). These immuno-
modulatory effects may contribute to the anti-tumor activity
of HDACi.
But some of the effects of HDAC inhibitors may also
hamper therapeutic efficacy. Examples are the increased
expression of multi-drug resistance proteins that lead to
increased cellular efflux of chemotherapeutic agents (Tabe
et al. 2006; Kim et al. 2008a, b).
HDAC inhibitors
A lot of effort has been put into the development of
HDAC inhibitors in recent years. Seven structurally
distinct classes of inhibitors are known today; inhibitors
of four different classes are now in clinical development
(see Table 1–6 for an overview). These classes comprise
hydroxamic acids, cyclic peptides, short-chain fatty acids,
and benzamides.
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was the first HDACi to be approved by the Food and Drug
Administration (FDA) in October 2006 for the treatment of
refractory cutaneous T-cell lymphoma for patients who had
received two or more prior systemic therapies. It has long
been considered to inhibit all zinc-dependent HDACs in the
low nanomolar range. Recent studies suggest that it has
only weak inhibitory effect on class IIa enzymes (Bradner
et al. 2010). Vorinostat induces cellular differentiation, e.g.,
of erythroleukemia cells, causes increased levels of p21 and
G1 cell cycle arrest. The compound inhibits cell growth in a
variety of different tumor cell lines and animal models with
little toxicity (Jones 2009).
With Romidepsin (Istodax®) (see Fig. 1), a structurally
different cyclic peptide (also called depsipeptide or FK-228
in the early literature), a second HDAC inhibitor was
Table 1 Vorinostat trials reported in 2009 and 2010
Combination therapy Type of cancer Phase N Outcome
(most relevant findings)
Literature
None Acute myeloid leukemia II 37 1 Response (group 3×200 mg) Schäfer et al.
(2009)
None Follicular (FL) and mantle cell
lymphoma (MCL)
I 10 40% Response; 2CRu, 1PR (FL);
1CRu (MCL)
Watanabe et al.
(2010)
None Solid tumors I 18 MTD was not reached Fujiwara et al.
(2009)
None Advanced prostate cancer II 27 2SD; all patients off therapy
before 6 months
Bradley et al.
(2009)
None Recurrent glioblastoma
multiforme
II 52 9 Progression-free after 6 month Galanis et al.
(2009)
Bortezomib Relapsed and refractory multiple
myeloma
I 23 42% Response rate; 3PR Badros et al.
(2009)
Peg-Lip-Doxorubicin,
Bortezomib
Relapsed/refractory Multiple
Myeloma
I 7 1CR, 1vgPR, 4PR Voorhees et al.
(2009)
a
Idarubicin, Cytarabine Acute myelogenous leukemia II 45 Response rate 80%;
35CR, 1CRP
Garcia-Manero
et al. (2009)
a
Lenalidomide, Dexamethasone Relapsed/refractory multiple
myeloma
I 25 Response rate 64%; 1CR,
1nCR, 2vgPR, 8PR, 4MR, 5SD
Siegel et al.
(2009)
a
Decitabine Acute myelogenous leukemia/
myelodysplastic syndrome
I MDS n=11
AML n=50
MDS: 2CR, 1PR, 1HI, 7SD
AML: 7CR, 4CRi, 2PR, 3HI, 26SD
Kirschbaum et
al. (2009)
a
Rituximab, Ifosphamide,
Carboplatin, Etoposide (ICE)
Relapsed/refractory lymphoid
malignancies, untreated
T-cell/mantle cell lymphoma
I 14 1CR, 2CRu, 9PR, 1SD Budde et al.
(2009)
a
pelvic palliative radiotherapy Gastrointestinal carcinoma I 16 MTD=300 mg once daily Ree et al. (2010)
5-FU, Leucovorin Metastatic colorectal cancer I/II 10 No MTD could be established;
2SD; study was closed
Wilson et al.
(2010)
Carboplatin, Paclitaxel Advanced stage NSCLC II 94 34% Response with Vorinostat vs
12.5% with Placebo
Ramalingam et
al. (2010)
Doxorubicin Solid tumors I 24 MTD=800 mg; 2PR (breast,
prostate cancer); 2SD (melanoma)
Munster et al.
(2009a)
5-FU, Leucovorin, Oxaliplatin Refractory colorectal cancer I 21 MTD=300 mg twice daily Fakih et al.
(2009)
Tamoxifen Advanced breast cancer II 29 6 Response; 3SD Munster et al.
(2009c)
a
Bortezomib Refractory solid tumors I 29 MTD 300 mg BID Ninan et al.
(2009)
a
Gemcitabine, Cisplatinum Advanced NSCLC I 28 9PR, 8SD Trédaniel et al.
(2009)
a
Erlotinib NSCLC I 13 6SD Reguart et al.
(2009)
a
Docetaxel Solid tumors I 12 No response Schneider et al.
(2009)
a
aMeeting report abstract
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isolated from Chromobacterium violaceum and inhibits the
activity of HDACs at low nanomolar levels. This natural
product is actually a prodrug which is activated by cellular
reduction to its active form, a dithiol (Furumai et al. 2002).
Romidepsin has been shown to inhibit human and mouse
tumor growth in different cancer models. This compound
inhibits preferably class I HDACs and is therefore called a
class-selective inhibitor in contrast to Vorinostat which also
acts strongly, e.g., on HDAC6 (Furumai et al. 2002; see
Fig. 1).
The most widely explored class of HDACi are the
hydroxamic acids. Besides, Vorinostat, seven additional
hydroxamate-based compounds are currently in different
stages of clinical development. Belinostat (PXD-101),
Panobinostat (LBH589), Dacinostat (LAQ824), and
SB939 are all cinnamic acid derivatives. Belinostat is a
potent HDACi with an IC50 in the low nanomolar region
(IC50 27 nM). The cytotoxic effects of this compound
correlate with hyperacetylation of histone H4 in tissue
culture. A dose-dependent growth reduction in ovarian and
colon xenograft models has also been observed (Plumb et
al. 2003; www.topotarget.com). Panobinostat is an orally
active HDAC inhibitor and has the highest inhibitory
potency among the clinically used hydroxamic acids. The
compound has been shown to increase the levels of p21 and
to induce hyperacetylation of histone H3 and H4. In vitro
and in vivo anti-tumor efficacy has been demonstrated in
different cell lines and xenograft models (Revill et al. 2007;
Atjada 2009). Dacinostat is structurally closely related to
Panobinostat and inhibits HDACs in submicromolar con-
centrations (IC50 0.15 μM). It has been shown to inhibit
cell growth and to induce apoptosis. Preclinical activity has
been demonstrated in colon, breast and lung cancer
xenograft models (www.hdaci.com; Catley et al. 2003).
Another cinnamic acid derivative is SB939. This compound
has favorable pharmacokinetic properties as it accumulates
in tumor tissue and shows a sustained hyperacetylation of
histones. In a colon xenograft model, it showed an almost
twofold greater effect in inhibition of tumor cell growth
compared to Vorinostat (Novoty-Diermayr et al. 2010).
Other hydoxamic acid based HDACis in clinical trials are
Givinostat (ITF2357), PCI 24781 and R306465 (JNJ-
16241199). These compounds are pan-HDACi; the latter
ones inhibit the enzyme activity in the low nanomolar
range. All three compounds show antiproliferative activities
and induction of histone hyperacetylation in different cell
lines. Preclinical efficacy has also been demonstrated in
tumor xenograft models (Jones 2009; Golay et al. 2007;
Arts et al. 2007) (see Fig. 2).
The structurally simplest class of HDACi are the short-
chain fatty acids. Despite the low inhibitory potency of
these inhibitors, also compounds from this class have been
studied in the clinic. Valproic acid, which has been used as
an antiepileptic drug for many years and still is used in this
indication, has been shown to inhibit preferably class I
HDACs in the high micromolar to millimolar range. The
compound induces differentiation of transformed cells and
causes hyperacetylation of histone proteins (Göttlicher et al.
2001). Due to the profound experiences in antiepileptic
therapy with manageable side effects, this compound is
investigated as an antileukemic agent in different trials
despite its low potency. Butyric acid is another short-chain
fatty acid. Because of its short half-life and low plasma
levels available, several prodrugs have been designed, of
which AN9/Pivanex was tested in the clinic (Rephaeli et al.
2000). Another rather weak HDACi is phenylbutyrate
which was reported to have antileukemic activity in a case
study (Warrell et al. 1998). Recent combination trials with
5-azacytidine showed only poor response (Lin et al. 2009;
see Fig. 3).
The fourth class of HDACi in clinical trials are the
benzamides or amino anilides. Their mechanism of inhibi-
tion on the molecular level was a subject of controversial
debate for several years now. Recently, Bressi et al. (2010)
could finally show that the amino anilide group indeed also
acts as a zinc-chelating moiety. CI-994 was the first
member of this group shown to inhibit HDACs with an
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Clin Epigenet (2010) 1:117–136 121IC50 between 25 and 50 μM. This compound entered
clinical trials but its investigation has been terminated
(Jones 2009). Entinostat (SNDX-275/MS-275) is a class-I-
selective inhibitor with an IC50 of 2 μM (Suzuki et al.
1999). It has also been shown to cause cell cycle arrest and
hyperacetylation of histone H4 (Saito et al. 1999).
Antitumor activity has been demonstrated in several tumor
cell lines and in different xenograft models (Hess-Stump et
al. 2007). Due to its relatively long half-life, weekly and
biweekly dosing schedules are explored in the clinic
(Hauschild et al. 2008). The third compound of this class
is Mocetinostat (MGCD0103). It is also a class-selective
HDAC inhibitor with IC50s in the submicromolar range.
Induction of histone hyperacetylation and apopotosis have
been shown as well as antiproliferative activities against a
wide panel of tumor cell lines and tumor growth inhibition in
multiple xenograft models (Fournel et al. 2008;s e eF i g .4).
Biomarkers
A lot of different surrogate markers have been investigated
due to their capacity to reflect the pharmacodynamic effects
of HDACi or to show a correlation with a response in
patients. The most extensively studied biomarker to date
has been the acetylation of target proteins pre- and post
treatment in PBMC or tumor tissue. Changes can be
determined via Western blot and flow cytometry analysis
or with immunohistochemical methods. This parameter was
analyzed in many clinical trials but a correlation between
the therapeutic response and a hyperacetylation of histones
or other target proteins was not found. Hyperacetylation of
target proteins was rather detected in basically all patients
treated with an HDACi, but at least a dose- and time-
dependent increase in acetylation levels could be observed
(Chung et al. 2006).
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of HDACi was reported by Bonfils et al. (2008; see Fig. 5).
The assay is based on the measurement of the HDAC
enzyme activity in living cells. The group therefore used a
small molecule, cell-permeable substrate that is converted
by HDACs (Hoffmann et al. 1999; Heltweg et al. 2003). In
a second step, the deacetylated substrate is cleaved into a
fluorophor with a longer wavelength shifted emission and a
lysine moiety by a protease-like trypsin. The fluorophor can
be quantitated by fluorescence intensity measurement. The
first results obtained with this assay reveal that the
measurement of the enzyme activity seems to be a
parameter with a greater dynamic range than the measure-
ment of histone acetylation levels. Thus, this parameter
may better reflect the pharmacodynamic effects of HDACi.
Whether a correlation between the HDAC enzyme activity
and the therapeutic response exists, needs to be determined
in future studies.
Furthermore, there are investigations ongoing to deter-
mine gene signatures that reflect the response to an HDACi
treatment. So far, first studies show that there are indeed
distinct changes in gene expression of certain genes
(Stimson et al. 2009). A microarray-based study of
Belinostat treated cell lines revealed a signature that is
selectively induced by HDACi compared to other chemo-
therapeutic agents (Monks et al. 2009). In another study
treatment of two different colon cancer cell lines with
Vorinostat and Panobinostat resulted in similar but cell line-
dependent changes in gene expression (La Bonte et al.
2009) Due to the multiple roles of the HDAC enzymes in
different pathways, it may be questionable whether a
defined gene signature can be identified at least for a
certain HDAC subtype selectivity profile. It is more likely
that this signature will strongly vary with tumor type, drug
exposure, and concentration. Another challenging question
will be the identification of changes in gene expression that
indicate the sensitivity to a treatment with HDACi.
The expression of the HDAC enzymes themselves was
suggested to serve as a predictive biomarker. Munster et al.
reported data from two clinical trials with HDACi where
they found a correlation of pretreatment HDAC2 expression
and histone acetylation in tumor tissue. No correlation was
found for HDAC6. Based on this data, HDAC2 expression
could serve as a predictive parameter to determine patients
who can benefit from HDACi treatment (Munster et al.
2009a, b).
Fantin et al. investigated the signal transducer and
activator of transcription (STAT) signaling pathway to
identify a biomarker predictive for Vorinostat response.
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STAT5 in lymphoma cell lines that poorly responded to
Vorinostat treatment compared to sensitive cell lines.
Consistent data came from immunohistochemical analysis
of pretreatment skin biopsies collected in a Vorinostat phase
IIb trial from nonresponder patients with cutaneous T-cell
lymphoma. Accumulation of STAT1 in the nucleus and
high nuclear levels of phosphorylated STAT3 correlated
with a lack in clinical response (Fantin et al. 2008). This
data suggests that deregulation of STAT activity may play a
role in Vorinostat resistance. Furthermore, the group could
show that coincubation of Vorinostat and a Jak inhibitor,
which blocks the STAT pathway, sensitizes cancer cell lines
previously resistant to Vorinostat treatment to the HDACi.
Cotreatment also leads to a synergistic effect in growth
inhibition, thus suggesting the combination of Vorinostat
and a Jak inhibitor to be a promising future treatment
option for patients resistant to Vorinostat therapy.
In a genome-wide loss-of-function screen, the protein
HR23B was identified to sensitize tumor cells to HDAC
inhibitors (Fotheringham et al. 2009). HR23B plays a role
in shuttling ubiquitinated cargo proteins to the proteasome
(Chen et al. 2009, 2002). Upon treatment with HDACi, it is
in part responsible for the deregulation of the proteasome
activity(Fotheringhametal.2009). An immunohistochemical
analysis of a collection of cutaneous T-cell lymphoma
(CTCL) skin biopsies obtained from a Vorinostat phase II
trial showed a correlation between HR23B expression and
clinical response. When relating the HR23B levels to clinical
response, a positive predictive value (PPV) of 71.7% could
be determined (Khan et al. 2010). Thus, HR23B expression
may serve as a predictive biomarker for HDACi treatment.
Garcia-Manero et al. linked an increased tolerance to
oxidative stress to Vorinostat resistance. A cDNA microarray
analysis performed during a phase I study of Vorinostat in
patients with advanced leukemia, revealed an upregulation of
expression of genes mainly coding for antioxidants in non-
responder patients (2008) .T h es a m eg r o u pc o n f i r m e dt h e s e
results in an HDACi-resistant leukemia cell line (Hu et al.
2010). Furthermore, they found that addition of β-phenylethyl
isothiocyanate, a compound that causes a decrease in the
cellular glutathione levels, resu l t e di ne n h a n c e dt o x i c i t yo f
Vorinostat in leukemia cell lines and primary leukemia cells
(Hu et al. 2010). Thus, the combination of an HDACi with an
inhibitor of the antioxidant pathway may sensitize non-
responder patients to an HDACi therapy.
Clinical trials of Vorinostat
Vorinostat was the first HDACi approved by the FDA for the
treatment of refractory cutaneous T-cell lymphoma. Currently,
it is investigated for other cancer types including both solid
tumors and hematologic malignancies. There were several
different trials reported in 2009 and 2010 for Vorinostat as
single agent and in combination therapy (see Table 1).
Trials in hematologic malignancies—mono therapy
A phase II study with 37 refractory acute myelogenous
leukemia (AML) patients showed only minimal activity of
Vorinostat. There was only one patient who responded to
therapy. Many others discontinued therapy before the
planned four cycles were administered due to failure of
Vorinostat to control the leucokyte count or due to patients’
or physicians’ preference (Schäfer et al. 2009).
In a small phase I study with ten Japanese patients with
malignant lymphoma who were treated with 100 or 200 mg
Vorinostat twice daily for 14 days followed by a 1 week rest
interval.In the cohort that received 200 mg BD, there were
two unconfirmed complete responses (CRu) and one partial
response (PR) in patients with follicular lymphoma and one
CRu in a patient who suffered from mantle cell lymphoma.
An increase in the acetylation levels of histone H3 with a
maximum effect 8 h after dosing could be seen, but also
only in the 200-mg cohort. Acetylation levels decreased to
baseline 24 h after dosing. No correlation between response
and histone hyperacetylation was found. In this study,
Vorinostat showed good activity, thus further investigations
in larger patient cohorts with malignant lymphoma are
warranted (Watanabe et al. 2010).
Trials in hematologic malignancies—combination therapy
Three trials were conducted with patients who suffered
from refractory multiple myeloma (MM). In two of these
studies, Vorinostat was administered in combination with
either the proteasome inhibitor Bortezomib alone or the
combination of Bortezomib and pegylated liposomal
Doxorubicine (Badros et al. 2009; Voorhees et al. 2009).
In the third trial, patients received Vorinostat in combina-
tion with Lenalidomide and Dexamethasone (Siegel et al.
2009). Overall response rates were 42%, 86%, and 84%,
respectively, and therapy was well tolerated in general.
Even though only small patient populations have been
investigated, these combinations demonstrated high clinical
activity. Remarkably, patients who received a prior therapy
with either Bortezomib or Lenalidomide and who were
refractory to their therapy responded again to the combina-
tion therapy. Due to these encouraging results, further
investigation of these combination therapy regimens with
larger patient collectives are warranted.
Two combination trials focussed on the treatment of
myelodysplastic syndromes (MDS) and AML (Kirschbaum
et al. 2009; Garcia-Manero et al. 2009). In one study, an
epigenetic combination therapy consisting of the DNA-
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inostat was administered. The other combination consisted of
Idarubicin, Cytarabine, and Vorinostat. Both trials revealed
good activity of these combinations with overall response
rates of 87% and 80%, respectively. No excess toxicity due to
Vorinostat was recognized. Another study investigated Vor-
inostat in combination therapy for the treatment of refractory
or relapsed lymphoid malignancies. Patients were treated with
Vorinostat in combination with Rituximab (R), which was
only administered in one subgroup, Ifosphamide (I), Carbo-
platin (C), and Etoposide (E) (V+RICE or V+ICE) (Budde et
al. 2009). Twelve of 14 patients responded to therapy, but
57% experienced gastro-intestinal adverse effects.
Taken together, Vorinostat in combination therapy
showed encouraging clinical activity in different haemato-
logic maligancies. Further studies should be conducted,
investigating the beneficial effect of Vorinostat compared to
the other combination partners.
Trials in solid tumor malignacies—mono therapy
Another trial with 18 Japanese patients investigated
Vorinostat in solid tumors. In this phase I study, 100 and
200 mg Vorinostat were administered twice daily or 400
and 500 mg were given once daily. The maximum tolerated
dose was not achieved even though the pharmacokinetic
profile was similar to the one established in non-Japanese
patients (Fujiwara et al. 2009). Disappointing results were
obtained in a phase II study of Vorinostat in patients with
advanced prostate cancer. Vorinostat was associated with
significant toxicities and all patients were taken off therapy
before 6 months. The best results were stable disease (SD)
achieved in two patients, but there was no PSA decline >50%
and 44% of the patients experienced grade 3 adverse effects
(Bradleyetal.2009). More encouraging results were reported
from a phase II trial of patients with recurrent glioblastoma
multiforme. Nine of 52 patients were progression-free after
6 months. Immunohistochemistry analysis revealved an
increase in histone acetylation post treatment compared to
baseline in five patients. Changes in gene expression of
genes shown to be regulated by Vorinostat could also be
demonstrated (Galanis et al. 2009).
Furthermore, Vorinostat was tested in several combination
therapy regimens for different types of cancer. In general, the
activity was higher than in the single agent trials, but in most
cases it has not been shown that the higher activity results
from the addition of Vorinostat to standard therapy.
Trials in solid tumor malignancies—combination therapy
There were also several trials of Vorinostat combination
therapy for solid tumors reported in 2009 and 2010. Two
trials focussed on the investigation of Vorinostat in
refractory colorectal cancer. Preclinical data showed that
Vorinostat is able to downregulate the expression of
thymidylate synthase (TS) in tumor tissue. As this protein
is the target enzyme of 5-fluorouracil, a synergistic effect of
this combination could be demonstrated in preclinical
experiments. Fakih et al. (2009) reported a phase I trial of
Vorinostat in combination with 5-fluorouracil, Leucovorin
and Oxaliplatin (Folfox). The maximum tolerated dose
(MTD) was determined to be 300 mg twice daily (BID) for
1 week every 2 weeks. However, a downregulation of TS
expression could only be detected in two out of six patients.
This data is consistent with the results of another phase I
study from Wilson et al. (2010). Only one out of ten
patients showed a decline in the intratumoral TS levels. The
biological activity of Vorinostat was determined by histone
H3 hyperacetylation in PBMC.
Another focus is the investigation of Vorinostat in
different combination regimes for the treatment of advanced
non-small cell lung cancer (NSCLC). Two trials combined
Vorinostat with platinum-based chemotherapies as well as
Paclitaxel and Gemcitabine (first regimen: Vorinostat,
Carboplatin,Paclitaxel;secondregimen:Vorinostat,Cisplatin,
Gemcitabine) (Ramalingam et al. (2009) ;T r é d a n i e le ta l .
2009). In the first study with the carboplatin-based regimen,
an increase in the response rate was seen in the group that
received Vorinostat as compared to placebo (34% vs.
12.5%). There was a trend towards improvement in
progression-free survival and overall survival. The
cisplatinum-based trial was a phase I study, in which the
MTD could be determined. In this study, Vorinostat could be
administered with standard doses of Gemcitabine and
Cisplatinum without additional toxicity. Seventeen from 19
patients responded to therapy.
The combination of Vorinostat and Erlotinib was also
tested for the treatment of NSCLC in patients with EGFR
mutations after Erlotinib progression. Preclinical experi-
ments suggested a reversal of erlotinib resistance of mutant
patients by Vorinostat treatment. The MTD was not
reached, but still six out of nine patients experienced stable
disease. Thus, this combination was well tolerated and
effective (Reguart et al. 2009). There were also combina-
tion trials of Vorinostat for patients with solid tumors of
different origin. One study investigated the combination of
Vorinostat and Docetaxel (Schneider et al. 2009). This trial,
however, was closed due to excessive toxicity. No objective
responses were seen. In another phase I study of Vorinostat
plus Bortezomib, the MTD could be determined at 300 mg
twice daily and bortezomib 1.3 mg/m
2. Besides that, there
was also evidence of clinical activity of this combination
(Ninan et al. 2009). Munster et al. (2009a) conducted a trial
of Vorinostat+weekly Doxorubicin. The MTD was deter-
mined to be 800 mg for 3 days every week of a 28-day
cycle. Two patients with breast and prostate cancer had a
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In this trial, the authors found a correlation between histone
hyperacetylation and pretreatment HDAC2 expression.
Another study from the same group focussed on the
combination of Vorinostat and Tamoxifen in breast cancer
patients who progressed despite prior hormone therapy
(Munster et al. 2009c). Preclinical experiments showed an
interference of HDACi with hormone receptor signaling,
thus nourishing the hope of reversing resistance to hormone
receptor modulators. HDACi have been shown to sensitize
ER-negative cell lines to Tamoxifen by inducing the release
of HDAC1 from the ERα-promoter and thus restoring
expression of ERα (Yang et al. 2001; Zhou et al. 2007)o r
by activation of ERβ (Hodges-Gallagher et al. 2006). In
ER-positive cell lines, HDACi cause a decrease in ERα-
expression (Reid et al. 2005; Rocha et al. 2005) and
sensitization of cells to Tamoxifen (Hodges-Gallagher et al.
2006; Hirokawa et al. 2005), which involves an upregula-
tion or translocation of ERβ (Duong et al. 2006; Jang et al.
2004). Six patients in this phase II study had an objective
response and three had SD that lasted longer than 6 months,
suggesting that this drug combination is feasible and that
HDACi may restore hormone sensitivity.
The first report of a clinical trial of the combination of an
HDACi with radiotherapy was reported by the group of
Flatmark (Ree et al. 2010). Vorinostat was combined with
pelvic palliative radiotherapy for the treatment of gastroin-
testinal carcinoma. The MTD was determined to be 300 mg
once daily. Most patients had a decrease in tumor volume
6weeksaftercompletionoftreatment.Thecombinationcould
be safely administered in general, suggesting an investigation
of Vorinostat in long-term curative pelvic radiotherapy.
Clinical trials of Romidepsin
Trials that lead to the approval of Romidepsin
The cyclic peptide Romidepsin is the second HDACi
approved by the FDA in November 2009 for the treatment
of CTCL of patients who had received at least one prior
systemic therapy. The approval was based on two single-arm,
multicenter, open-label trials in which 167 patients were
treated (Kim et al. 2008a, b; Piekarz et al. 2009a, 2009b).
Romidepsin can be administered at 14 mg/m
2 intravenously
over 4 h on days 1, 8, and 15 of a 28-day cycle. Overall
response rates were similar in both studies (34% and 35%).
Six resp. four patients had a complete response whereas 27
resp. 20 patients achieved a PR. The duration of response
was remarkably long; 14.9 and 13.7 months, respectively.
Adverseeffectsincludednausea,fatigue,infections,vomiting,
anorexia, anemia, thrombocytopenia, neutropenia, lymphope-
nia, and ECG T-wave changes. Besides its approval for
CTCL, Romidepsin is investigated as a treatment option in
other cancer types as monotherapy as well as in combination
therapy (see Table 2).
Trials in hematologic malignancies
Encouraging results came from a phase II multicenter trial of
patients with relapsed peripheral T-cell lymphoma (PTCL;
Piekarz et al. 2009a, b). Forty-six patients were treated; the
overall response rate was 33%. Five patients showed a
complete response and ten patients a partial remission.
Noteworthy, like in CTCL patients, is the long duration of
response (9 months). Adverse effects were generally mild.
Currently, a phase IIb protocol is ongoing in multiple
centers. A combination of Romidepsin and Bortezomib is
currently being investigated in a phase II study in patients
with refractory MM (Berenson et al. 2009a, b). So far, five
patients have been treated with 10 mg/m
2 Romidepsin on
days 1, 8, and 15 and 1.0 mg/m
2 Bortezomib on days 1, 4,
8, and 11 of a 28-day cycle. Two of them, who relapsed
from Bortezomib-containing regimes in a prior therapy, had
minimal responses. Because of two patients, who experi-
enced a grade 3 thrombocytopenia, additional patients are
treated with a reduced dose of Romidepsin (8 mg/m
2).
Trials in solid tumor malignancies
Little clinical activity of Romidepsin was noted so far in the
treatment of solid tumors. The results of two trials were
Table 2 Romidepsin trials reported in 2009 and 2010
Combination therapy Type of cancer Phase N Outcome (most relevant findings) Literature
None Cutaneous T-cell lymphoma II 71 Response rate 34% 4CR, 20PR Piekarz et al. (2009a, b)
None Cutaneous T-cell lymphoma II 27 2CCR, 13PR Kim et al. (2008a)
a
None Relapsed peripheral T-cell lymphoma II 46 5CR, 10PR Piekarz et al. (2009a, b)
a
None Metastatic castration-resistant prostate cancer II 35 2PR Molife et al. (2010)
None Advanced colorectal cancer II 25 4SD; No objective response Whitehead et al. (2009)
Bortezomib Refractory multiple myeloma II 5 2 Minimal responses Berenson et al. (2009a, b)
a
aMeeting report abstract
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metastatic, castration-resistant prostate cancer revealed
minimal clinical activity of Romidepsin (Molife et al.
2010). Two patients had a partial response that lasted
longer than 6 months with a PSA decline of over 50%, but
there were also 11 patients who had to discontinue the
medication due to toxicity. Another phase II study of 25
patients with advanced colorectal cancer was closed due to
a lack of activity (Whitehead et al. 2009). No objective
responses have been seen; four patients had stable disease
as the best result. As for now, Romidepsin has shown
promising clinical activity in hematologic malignancies
other than CTCL but only weak efficacy in the treatment of
solid tumors was observed.
Clinical trials of Panobinostat
Trials in hematologic malignancies—mono therapy
The hydroxamate Panobinostat showed activity in clinical
trials with different hematologic malignancies (see Table 3).
Younes et al. (2009) reported encouraging data from a
phase II trial of oral Panobinostat in patients with Hodgkin
lymphoma after high-dose chemotherapy with autologous
stem cell transplant. Of 53 patients treated for at least two
cycles, one patient achieved a complete response, ten
patients had a partial response and 31 patients experienced
stable disease. Noteworthy, 77% of the patients experienced
thrombocytopenia as a grade 3/4 adverse effect, which,
however, was reversible after 7–8 days after discontinuation
of therapy. This data indicates good clinical activity of
Panobinostat in combination with manageable toxicity in
pretreated Hodgkin lymphoma patients.
Two trials focussed on the investigation of Panobinostat
in patients with myelofibrosis (DeAngelo et al. 2009;
Mascarenhas et al. 2009). Preliminary data indictates that
in both studies, some patients received a significant
reduction in spleen size as well as an improvement in other
disease-related symptoms, e.g., a reduction in transfusion
requirements or transfusion independence. One previously
untreated patient received a PR. From this first data,
Panobinostat appears to be a promising new agent in the
therapy of myelofibrosis, thus further investigation is
warranted.
Trials in hematologic malignancies—combination therapy
A major focus is the investigation of Panobinostat in
different combination regimes for the treatment of refrac-
tory MM. Results from three studies in 2009 is available.
Berenson et al. (2009b investigated the combination of
Panobinostat and Melphalan). In the dose-finding part of
the study, several dose adjustments were necessary due to
toxicity. Grade 3 neutropenia, thrombocytopenia, and
severe fatigue occurred in most patients. Currently, the
modified protocol (20 mg Panobinostat on days 1, 3, 5, 8,
10, and 12; 0.05 mg/kg melphalan on days 1, 3, and 5 of a
Table 3 Panobinostat trials reported in 2009 and 2010
Combination
therapy
Type of cancer Phase N Outcome (most relevant findings) Literature
None Relapsed/refractory
Hodgkin lymphoma
II 53 1CR, 10PR, 31SD Younes et al.
(2009)
a
None Myelofibrosis (MF) I 176 (thereof 13
with MF)
MF:1PR, 3CI DeAngelo et al.
(2009)
a
None Myelofibrosis I 8 2CI; 4SD Mascarenhas et al.
(2009)
a
Lenalidomid,
Dexamethasone
Multiple myeloma I 22 5/10 mg Panobinostat: regarded as safe Spencer et al.
(2009)
a
Bortezomib Relapsed multiple myeloma I 28 64% Response: 4CR; 10PR; 4 minor
responses
San-Miguel et al.
(2009)
a
Melphalan Multiple myeloma I 12 1CR; 3PR; 4SD Berenson et al.
(2009a, b)
a
Imatinib Chronic myeloic leukemia I 5 MTD to be determined Bhatia et al.
(2009)
a
Docetaxel Castration-resistant prostate
cancer
I 16 no effects as single agents; 5 patients with
PSA decline >50%
Rathkopf et al.
(2010)
Trastuzumab HER-2 positive metastatic
breast cancer
I 18 Conte et al. (2009)
aMeeting report abstract
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combination shows encouraging clinical activity with a
disease control rate of 67% including one CR, three PR,
and four SD. If the modified protocol results in a
manageable toxicity, this drug combination is a promising
treatment option for multiple myeloma patients. Similar
results came from a combination study of oral Panobinostat
and Bortezomib (San-Miguel et al. 2009). The overall
response rate in this study was 64% including four CR and
a response of patients, refractory to their prior Bortezomib
therapy. However, significant thrombocytopenia occurred
in many patients, thus warranting a dose adjustment or an
alternative dosing schedule in further studies to receive a
better safety profile.
A third combination study for the treatment of multiple
myeloma focussed on the combination of Panobinostat with
Lenalidomide and Dexamethasone (Spencer et al. 2009). So
far, dose escalation studies are ongoing with Panobinostat,
5 and 10 mg three times a week, combined with 25 mg
Lenalidomide four times daily on days 1–21 and 40 mg
Dexamethasone on days 1–4, 9–12, and 17–20 of a 28-day
cycle appeared to be safe. Due to these encouraging results
from the MM treatment trials, a randomized, double blind,
placebo controlled phase 3 study (PANORAMA-1) of
PanobinostatincombinationwithBortezomibandDexameth-
asone for the treatment of relapsed MM has started global
enrollment at the end of 2009 (http://www.novartisoncology.
com/research-innovation/pipeline/Panobinostat.jsp).
Panobinostat has also been investigated for the treatment
of chronic myeloic leukemia in combination with Imatinib
(Bhatia et al. 2009). Preliminary results are available so far:
two patients showed a reduction in the BCR-Abl levels as
detected by qPCR from bone marrow aspirates. The MTD
has not been reached yet.
Trials in solid tumor malignancies
Only few data exists for the treatment of solid tumors with
Panobinostat. In a combination study of oral Panobinostat
versus oral Panobinostat plus Docetaxel in patients with
advanced prostate cancer, all patients in the Panobinostat
mono-therapy arm progressed under therapy, despite of
detectable levels of histone hyperacetylation in PBMCs,
whereas five out of eight patients in the combination arm
showed a PSA decline >50% (Rathkopf et al. 2010).
Further studies need to investigate if there is a clinical
benefit of the combination in comparison to a Docetaxel
monotherapy. The same group is currently investigating the
combination of i.v. Panobinostat and Docetaxel. The
combination of either oral or i.v. Panobinostat and
Trastuzumab is being investigated in women with meta-
static HER2-positive breast cancer (Conte et al. 2009). The
dose finding is ongoing. Patients of cohort 1 who received
10 mg Panobinostat three times weekly or 15 mg Panobi-
nostat i.v. on days 1 and 8 of a 21-day cycle in combination
with weekly Trastuzumab tolerated the study medication
well. So far, two patients showed a reduction in tumor size.
Clinical trials of Belinostat
Trials in hematologic malignancies
Belinostat is another hydroxamate-based HDACi in late
stage clinical development (see Table 4). Two trials for the
treatment of hematologic malignancies have been reported
in 2009. A phase I study aimed to determine the adequate
dosing and safety of oral Belinostat in patients with
lymphoma (Zain et al. 2009). Belinostat was given in doses
Table 4 Belinostat trials reported in 2009 and 2010
Combination
therapy
Type of cancer Phase N Outcome (most relevant findings) Literature
None Lymphoma I 9 6SD; tumor shrinkage of 43
and 49% in two patients after
cycle 2
Zain et al. (2009)
a
None Peripheral/Cutaneous
T-cell lymphoma
II 20 (PTCL)
29 (CTCL)
PTCL: 2CR, 3PR, 5SD
CTCL: 2CR, 2PR, 17SD
Pohlmann et al.
(2009)
a
None Platinum resitant epithelial ovarian
cancer (EOC)+Micropapillary
ovarian tumors (LMP)
II 32 1PRu, 10SD (LMP); 9SD (EOC) Mackay et al.
(2010)
None Advanced malignant pleural
mesothelioma
II 13 2SD; No objective response; 1 death
(cardiac arrhythmia)
Ramalingam et al.
(2009)
None Solid tumors I 92 33SD Kelly et al. (2009)
a
None Thymic malignancies II 22 2PR; 13SD Giaccone et al.
(2009)
a
aMeeting report abstract
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cycle. Nine patients have been enrolled until now, with
three per cohort. No dose-limiting toxicity has occurred so
far, only one grade 3 and 4 thrombocytopenia has been
noticed. The most frequent adverse events were anorexia,
fatigue and diarrhea. Five out of six patients evaluable for
efficacy showed stable disease. A tumor shrinkage of 43–
49% has been observed in three patients after cycle two.
Based on this data, Belinostat can be safely administered in
patients with myeloma.
Pohlmann et al. (2009) investigated i.v. Belinostat in
patients with PTCL, and CTCL. In this phase II study,
patients received 1,000 mg/m
2 Belinostat over 30 min on
days 1–5 of a 21-day cycle. Out of 20 PTCL patients, two
responded with a complete response and two others with a
partial remission. Stable disease was observed in five
additional patients. Two of the CTCL patients had a CR
and PR, respectively. Remarkably, the time to response was
only 16 days. Seventeen additional CTCL patients achieved
stable disease. Therapy was well tolerated in general; only
one grade 3 neutropenia and one thrombocytopenia were
noted. These results represent the basis for the conduction
of the BELIEF study, a pivotal study of Belinostat in
patients with PTCL.
Trials in solid tumor malignancies
The clinical activity of Belinostat is also being investigatedin
solid tumor malignancies. A phase I study of patients with
solid tumors were investigated using different doses and
dosing schedules of oral Belinostat (Kelly et al. 2009).
Ninety-two patients have been included. The most frequent
adverse effects were fatigue, nausea, anorexia, vomiting,
and diarrhea. Different therapy regimens were tested. The
drug was given either continously, or for the first 2 weeks;
respectively for the first 5 days of a 3-week cycle. The
recommended dose for continuous dosing is 250 mg once or
twice a day and for days 1–14 dosing, 750 mg once a day is
recommended. The dose-finding for days 1–5 dosing has
not been completed yet. With regard to efficacy, 33 patients
had stable disease, thus making Belinostat an interesting
option for further investigations in special tumor types.
Promising results also came from a phase II study of
Belinostat in patients with thymic malignancies (Giaccone
et al. 2009). These tumors are very rare and no second-line
therapy for patients with refractory disease exists. A total of
22 patients, 14 with thymoma and eight with thymic
carcinoma, have been accrued. Two partial responses were
seeninpatients withthymoma,while13additionalpatientshad
stable disease. Nausea was the most common adverse effect,
which could be controlled with prophylactic antiemetics. All
analyzed patients showed an accumulation of acetylated
histones and tubulin in monocytes and lymphocytes analyzed
by multiparameter flow cytometry.
Another phase II study with Belinostat for patients with
malignantpleuralmesotheliomawasreportedbyRamalingam
et al. (2009). Thirteen patients with advanced disease were
treated with 1,000 mg/m
2 Belinostat for 5 days every 3 weeks
and two cycles were administered. Two patients had stable
disease but there were no objective responses. One possibly
study-related death occurred, where the patient died of
cardiac arrhythmia. In this dosing schedule, Belinostat is
not active as monotherapy, suggesting further investigations
of different dosing schedules or in combination with other
chemotherapeutics.
Kelly et al. reported data from a phase II study of
Belinostat in women with platinum-resistant epithelial
ovarian cancer (EOC) and micropapillary (LMP) ovarian
tumors (Mackay et al. 2010). These tumors are rarely
included into clinical trials and have a poor prognosis.
Belinostat was administered at 100 mg/m
2 over 30 min on
days 1–5 every 3 weeks. Of the LMP patients, one achieved
a partial response (unconfirmed) and ten had stable disease
whereas nine patients with EOC had stable disease as best
result. The progression-free survival was 13.4 months for
LMP patients and only 2.3 months for EOC patients. The
most common side effect was fatigue. An accumulation of
acetylated histones could be observed in tumor tissue and
PBMC regardless of response.
Trials of Givinostat
Givinostat is a hydroxamic acid containing HDACi which
is currently in early clinical development (see Table 5).
Data of a phase II trial in patients with relapsed or
progressive multiple myeloma was reported by Galli et al.
(2010). The first part of the study focussed on the dose
Table 5 Other hydroxamate and anilide HDACi trials reported in 2009 and 2010
Study medication Type of cancer Phase N Outcome (most relevant findings) Literature
Givinostat Relapsed/progressive multiple myeloma II 19 5SD; MTD 100 mg twice daily Galli et al. (2010)
Mocetinostat Advanced chronic lymphocytic leukemia II 21 No response Blum et al. (2009)
Entinostat+5-Azacytidine Myeloid Malignancies I 38 3 CR, 4 PR, 7 HI Fandy et al. (2009)
aMeeting report abstract
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for four consecutive days every week of a 28-day cycle. As
two patients experienced dose-limiting toxicities at this
dose, the next patients received 100 mg twice daily, which
was determined to be the maximum tolerated dose. At the
lastfollow-up, there were five patients with stabledisease, but
serious adverse effects occurred in four patients (gastrointes-
tinal toxicity, transient electrocardiographic abnormalities)
and all but one patient developed a thrombocytopenia. Based
on this data, Givinostat showed modest clinical activity with
tolerable toxicity.
Trials of PCI-24781
The hydroxamate HDACi PCI-24781 is being developed
by Pharmacyclics and is currently in phase I and II studies
of clinical development. The compound has been investi-
gated in a phase I/II study for the treatment of lymphoma.
Twenty-five patients have been enrolled to date and 15
have been evaluated (http://www.pharmacyclics.com/pdf/
PCI-24781_HDAC_Inhibitor_Exec_Overview_Oct09.pdf).
Two patients achieved a partial response, nine showed
stable disease. In a phase I dose-finding study in patients
with solid tumors, five of 25 evaluable patients had stable
disease. No QTc prolongation was noticed. Another phase
II study of the combination of PCI-24781 with doxorubicin
for patients with advanced sarcoma started at the end of 2009
(http://www.pharmacyclics.com/pdf/PCI-24781_HDAC_
Inhibitor_Exec_Overview_Oct09.pdf).
Trials of Mocetinostat
The class I-selective benzamide HDACi Mocetinostat has been
investigated in different phase 1 and 2 studies for hematologic
malignancies and solid tumors (see Table5). In 2008, the FDA
put a partial hold on Mocetinostat due to some cases of
pericarditis/pericardial effusion (http://www.methylgene.com/
content.asp?node=324). Patients that were currently enrolled
in clinical trials and did not show any symptoms of pericardial
disease could continue their study. The hold was lifted in
2009, thus patient enrollment could be continued (http://www.
ebionews.com/news-center/enterprise-a-industry/34-business-
development/8035–methylgene-to-resume-development-of-
its-hdac-inhibitor-mgcd0103-mocetinostat-.html).
Data of a phase II trial in patients with advanced chronic
lymphocytic leukemia was reported in 2009 (Blum et al.
2009). Patients received 85 mg Mocetinostat a day, three
times weekly. A dose escalation to 110 mg or the addition
of Rituximab was permitted after two or more cycles
without response. No responses were obtained in this study.
Three patients received 110 mg and four others additional
Rituximab without an improvement in response. Grade 3
and 4 toxicities were infections, thrombocytopenia, anemia,
diarrhea, and fatigue. HDAC inhibition was demonstrated
in six out of nine patients on day 8. In this clinical setting,
Mocetinostat showed limited anti-cancer activity; further
investigations should therefore focus on combination
therapy.
Trials of Entinostat
Data of one clinical trial with the benzamide Entinostat was
reported in 2009 (seeTable 5). Fandy et al. (2009) investigated
the combination of Entinostat and 5-Azacytidine in patients
with myeloid malignancies. Patients were treated for ten
consecutive days with 30, 40, or 50 mg/m
2 5-Azacytidine and
received 2, 4, 6, or 8 mg/m
2 Entinostat orally on days 3 and
10 of a 28- or 29-day schedule. Among 30 patients who
received at least four cycles of therapy, three patients had a
CR, four had a PR, and seven patients showed hematologic
improvements. This result indicates a greater clinical activity
of this epigenetic combination therapy, compared to single
agent Entinostat, that showed limited benefit in advanced
acute leukemias so far (Gojo et al. 2007). There are also
several active trials ongoing (http://www.syndax.com/
trials_studies.aspx). Entinostat is being investigated as a
single agent in patients with relapsed/refractory Hodgkin’s
lymphoma. A dose of 10 mg is administered from days 1 to 5
of 28-day cycle. This dose can be expanded to 15 mg if no
dose-limiting toxicity occurs. Entinostat in combination with
GM-CSF is being explored in patients with myelodysplastic
syndromes, acute myeloid leukemia, and chronic myelocytic
leukemia. Patients with these malignancies are also treated
with Entinostat as monotherapy or in combination with 5-
Azacytidine.
Studies in patients with solid tumor malignancies are also
ongoing. Non-small cell lung cancer patients are being treated
with single agent Erlotinib or the combination of Erlotinib and
Entinostat. Another trial for the same type of cancer investi-
gated the combination of Entinostat and 5-Azacytidine. Two
trials with women suffering from breast cancer explore the
combination of Entinostat and different aromatase inhibitors,
respectively. Because of these active trials, an update on the
clinical activity of Entinostat can be awaited soon.
Trials of valproic acid
Trials in hematologic malignancies
Even though the carboxylic acid valproate (VPA) is an
HDACi with weak inhibitory potential, it is an interesting
drug for clinical trials due to its well-characterized
130 Clin Epigenet (2010) 1:117–136pharmacodynamic and pharmacokinetic profile (see Table 6).
Several combination trials of valproate were reported in 2009
and 2010. An epigenetic combination therapy consisting of
valproic acid and 5-Azacytidine (Vidaza®) was investigated
in patients with intermediate and high risk MDS (Voso et al.
2009). Patients received VPA in doses to achieve a plasma
level of 50 μg/ml in combination with 75 mg/m
2 5-
Azacytidine for 7 days of a 28-day cycle. From 26 patients
who completed eight cycles of therapy, 30.7% achieved a
complete or partial remission. Fifteen point four percent
showed major hematologic improvements and 38.5%
showed SD. The drug-related toxicities were reported to be
mild. This epigenetic therapy is active in MDS patients with
a poor prognosis and can safely be applied.
Raffoux et al. (2010) treated patients for six cycles with
the above-mentioned epigenetic combination therapy of
VPA and 5-Azacytidine for 7 days and additional doses of
all-trans retinoic acid (ATRA) for 21 days. Among the 65
patients who were enrolled in this study, 14 received a PR
and three a CR. Interestingly, overall survival in patients
who received the planned six cycles was not dependent on
CR or PR; that means that stable disease during treatment
correlates with survival. Furthermore, an early platelet
response and promoter demethylation of four genes
(FZD9, ALOX12, HPN, and CALCA) was associated with
clinical response. However, the beneficial effect of ATRA
remains questionable as the response rates in this study
were not superior to those of earlier studies with the
combination of VPA and 5-Azacytidine. Further trials are
needed to prove the benefit of adding ATRA to the
epigenetic combination therapy.
Trials in solid tumor malignancies
Two trials focussed on the investigation of different VPA
combinations in Myeloma treatment. Daud et al. (2009)
treated 39 patients who suffered from myeloma stage IV
with the combination of VPA and a new topoisomerase-I-
inhibitor, Karenitecin. The MTD was 75 mg/kg/day VPA
on days 1–5 combined with Karenitecin 1.0 mg/m
2/day in a
28-day cycle. Somnolence occurred as a dose-limiting-
toxicity. Of 33 patients evaluable for response, 47%
achieved stable disease. The overall survival was
32.8 weeks. Histone hyperacetylation was observed in
PBMC.
In another phase I/II study with advanced melanoma
patients, valproate was combined with Dacarbazine plus
interferon-α (Rocca et al. 2009). As a first part of the study,
patients received Valproate monotherapy for 6 weeks. The
dose was adjusted by measuring inhibition of HDAC
activity in PBMC during therapy with the goal to achieve
a measurable inhibition of the target. In the second part,
Dacarbazine and interferon-α were added. Twenty-nine
patients received VPA monotherapy whereas only 18
received the combination of the three drugs. From the
patient treated with the combination regime, one achieved a
CR and two a PR. Three additional patients had stable
disease, lasting longer than 24 weeks. In this study,
valproate did not show results superior to melanoma
standard therapy with non-negligible toxicity, thus ques-
tioning the clinical benefit of VPA in this clinical setting.
A phase I/II trial of Valproate in combination with
Epirubicin or the combination of 5-Fluorouracil, Epiru-
bicin, and Cyclophosphamide (FEC100) for patients
with solid tumors was conducted by Munster et al.
(2009b). In the first part, 44 patients received escalating
doses of valproate with a fixed dose of Epirubicin. The
MTD was determined to be 140 mg/kg/day, nine patients
achieved a partial response. During the second part of the
study, a disease-specific cohort of 15 breast cancer patients
were treated with 120 mg/kg/day Valproate and the
combination regime FEC100. Nine out of 14 patients
responded to therapy. Overall, somnolence was the most
n o t e da d v e r s ee f f e c tr e l a t e dt oV a l p r o a t e ,w h e r e a sE p i -
rubicin caused myelosuppression. The biological activity
of Valproate was measured via histone acetylation in
PBMC. The acetylation levels correlated with VPA serum
levels and could be linked to baseline HDAC2—but not
HDAC6 expression. This combination shows promising
activity in the treatment of solid tumors. A randomized,
double-blind study has to reveal if there is a clinical
benefit of VPA.
Table 6 Valproate trials reported in 2009 and 2010
Combination therapy Type of cancer Phase N Outcome (most relevant findings) Literature
5-Azacytidine High risk MDS II 62 8CR/PR, 4HI, 10SD Voso et al. (2009)
5-Azacytidine+ATRA High risk AML, MDS II 65 14PR, 3PR Raffoux et al. (2010)
I Epirubicin Solid tumors I/II I 41 I 9PR Munster et al. (2009b)
II FEC100 II 14 II 9 objective response
Karenitecin Melanoma I/II I 33 I MTD=75 mg/kg/day Daud et al. (2009)
II 15 II 7SD
Dacarbazine+IFα Melanoma I/II 18 1CR, 2PR, 3SD Rocca et al. (2009)
Clin Epigenet (2010) 1:117–136 131Conclusion and further perspectives
HDAC inhibitors are promising new agents in targeted anti-
cancer therapy. Two compounds, Vorinostat and Romidepsin,
are already approved by the FDA for the treatment of
refractory cutaneous T-cell lymphoma. Several other inhib-
itors are in late stages of clinical development for cancer
therapy. It will be interesting to see whether some of the new
compoundswillhavebenefitsintermsofincreasedefficacyor
reduced side effects and whether those effects can be
correlated with the HDAC subtype selectivity profiles, certain
chemical substructures (hydroxamates vs. benzamdes) or
might be substance specific. Data of clinical trials indicates a
higher activity of HDACi in hematologic malignancies,
whereas mostly little or no clinical benefit was observed in
solid tumor malignancies.
Remarkably, synergistic effects result from the combi-
nation treatment of HDACi with different chemotherapeu-
tics, other epigenetic drugs or target-based agents, as well
as radiotherapy. In the majority of the trials reported, the
HDACi could be applied in combination with standard
doses of other drugs without additional toxicity but
synergistic clinical activity, thus suggesting a promising
role of HDACi in cancer combination therapy.
Even though there were a lot of concerns regarding toxic
side effects of HDACi in the clinical setting due to the roles
of HDACs in multiples pathways, until now clinical trials
mostly showed manageable side effects. Cardiotoxic effects
are regarded as a class effect in the group of HDACi and a
hold was put on the clinical development of Mocetinostat in
2008, but only in a few cases, prolongation of the QT
interval has been detected in the clinic. This fact may be
due to preselection of patients in clinical trials; therefore,
the incidence of cardiotoxic effects in unselected patient
populations needs to be critically monitored.
In almost every HDACi clinical trial, there were patients
resistant to HDACi therapy. Until today, the mechanisms of
resistance to HDACi are understood only to a small extent.
Deregulated STAT activity and upregulation of certain
antioxidant -genes seem to play a role in HDACi resistance.
Further work needs to be conducted to fully elucidate the
pathways responsible for HDACi resistance so that more
patients can benefit from this therapy.
Until now, no differences in the clinical activity and
adverse effects could be determined between the pan-
HDACi and the class-selective compounds. Thus, the
hypothesis that compounds that target selectively one
HDAC isoform will reveal a greater clinical benefit
combined with a better toxicity profile has yet to be
proven. Along with the development of these isoform-
selective inhibitors, the biological roles and the roles in
cancer of the individual isoforms need to be further
elucidated. Experiments with HDAC knockout mice
showed a fundamental role of the different HDACs in
human development (Haberland et al. 2009). HDAC1,
HDAC3, HDAC7 knockout mice are embryonic lethal,
HDAC2 and HDAC4 knockouts die shortly after birth.
Only HDAC5, HDAC6, and HDAC9 knockout mice are
viable. Remarkably, the different HDAC isoforms seem to
be involved in quite different processes of embryonic
development. Whereas HDAC2 plays a role in heart
development, HDAC4 controls the formation of the
skeleton and HDAC7 is involved in the formation of the
endothelium (Haberland et al. 2009). These findings will
contribute to a better understanding of the biological roles
of the different HDAC isoforms and thus will finally lead to
the development of new and more selective HDACi. Also,
the relative roles of deacetylation of histones vs. other
substrate proteins with respect to the clinical response have
to be dissected further.
In the future, it also needs to be determined if the so
called epigenetic drugs really exert their effects through
altering misregulated epigenetic states or just through
transcriptional regulation processes. Until today, it is
unclear what mechanisms cause the clinical effects of
HDACi. Only with an improved understanding of the mode
of action of HDACi, it will be possible to develop more
potent and selective inhibitors.
Another goal for future clinical trials is the search for
new and better biomarkers to monitor the effects of
HDACi. The detection of target protein hyperacetylation
only serves to show that the inhibitors hit their target but
there is no correlation with clinical response. The measure-
ment of the enzyme activity in surrogate cells or tumor
tissue seems to have a greater dynamic range but future
studies have to prove the usefulness of this parameter.
Furthermore, in a time of personalized medicine, it is also
important to find biomarkers that predict the response resp.
resistance to HDACi treatment. Recently, the protein
HR23B was suggested to serve as such a predictive
parameter. Further analysis of more patient samples need
to confirm these initial results.
Besides the clinical development of HDACi for cancer
therapy, there is growing evidence that these inhibitors also
have a therapeutic potential for the treatment of neurolog-
ical disorders (Kazantsev et al. 2008). Until today, several
HDACi showed positive effects in different preclinical
models of Alzheimer’s disease, Huntington’s disease and
other neurologic malignancies. The HDACi 4b has been
shown to improve the disease phenotype with low toxic
effects in a mouse model of Huntington’s disease (Thomas
et al. 2008). Kilgore et al. (2010) could show that the
HDACi Vorinostat, sodium valproate, and sodium butyrate
were able to restore cognitive function in a transgenic
mouse model of Alzheimer’s disease. Due to these
encouraging results from preclinical studies, clinical devel-
132 Clin Epigenet (2010) 1:117–136opment seems to be plausible in the future, even though
there are still a lot of challenges to overcome, e.g.,
penetration of compounds through the blood–brain barrier.
To summarize, HDACi are a new class of drugs with a
therapeutic potential not only in cancer but also in
neurologic disorders and there may be other therapeutic
indications that are on the horizon but need clinical
confirmation.
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